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Introduction: Clinical synovitis is often associated with damage to bone and cartilage. Previous data have suggested
that joint erosions (JE) are more prevalent than joint space narrowing (JSN) and that the two processes are partly
independent of each other. The objective of this study was to evaluate whether the presence of JE in an individual
joint can lead to development of JSN and if existing JSN leads to new onset of JE, in the absence of synovitis.
Methods: The Prospective Multi-Centre Randomised, Double-Blind, Active Comparator-Controlled, Parallel-Groups
Study Comparing the Fully Human Monoclonal Anti-TNFα Antibody Adalimumab Given Every Second Week With
Methotrexate Given Weekly and the Combination of Adalimumab and Methotrexate Administered Over 2 Years in
Patients With Early Rheumatoid Arthritis (PREMIER) enrolled early rheumatoid arthritis (RA) patients who were
randomized to one of three treatments: methotrexate (MTX), adalimumab (ADA), or ADA +MTX. All evaluable joints
with JE and JSN measures at 26 and 52 weeks and synovitis assessments from week 26 to 52 were included. Synovitis
was assessed every 2–8 weeks by swollen joint counts between weeks 26 and 52. Radiographs were taken at week 26
and 52. Two readers, blinded to time and sequence, scored 14 bilateral joints individually for JE and JSN. Multivariate
logistic modeling was used to characterize the dependence of JE/JSN onset at 52 weeks. Analyses were performed
based on treatment arm and were also performed within individual joints.
Results: JE and swelling were independently and comparably associated with onset of JSN at week 52. Assessment by
individual joints indicated that existing JE, independent of swelling, was significantly associated with JSN onset in
higher proportions of metatarsophalangeal (MTP; 7/10) than proximal interphalangeal (PIP; 1/8) or
metacarpophalangeal (MCP; 1/10) joints. Treatment with ADA +MTX prevents JE/JSN progression independently of its
ability to suppress synovitis and limits JE/JSN onset and progression in joints with existing damage.
Conclusions: Existing JE predisposes individual joints to development of JSN independently of synovitis in the same
joint. Weight-bearing MTP joints with JE may be at increased risk for JSN when compared with MCPs and PIPs.
Trial registration: Clinicaltrials.gov NCT00195663. Registered 13 September 2005.Introduction
Rheumatoid arthritis (RA) is characterized by inflamma-
tion of the synovial membrane, which can result in joint
destruction within the first few years after onset [1-3].
Inflammation and joint damage can result in a loss of
physical function, which is a hallmark of progressive dis-
ease [4-7]. Damage to the bone is measured through
joint erosion (JE), while cartilage injury is approximated* Correspondence: Landewe@rlandewe.nl
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stated.by measuring joint space narrowing (JSN). Although
JSN is likely a marker for loss of cartilage, it may also re-
flect damage to other soft tissues. JE has historically
been perceived to be a critical indicator of permanent
disability in RA patients; however, recent data suggest
that JSN, occurring early in disease process, may be a
more important determinant of irreversible physical dis-
ability [8,9].
The combination of a tumor necrosis factor (TNF) in-
hibitor plus methotrexate (MTX) reduces the risk of
joint damage onset or progression and improves physicalal. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
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Patients treated with combination therapy tend to have
minimal or no progression of joint damage, regardless of
the level of inflammation, while the level of joint damage
tends to reflect the extent of inflammation in MTX mono-
therapy [16-20]. This suggests that combination therapy
may inhibit joint damage through mechanisms that are in-
dependent of inflammatory activity or that the extent of
the biological inflammatory response required for the acti-
vation of destructive mechanisms may be higher than is
needed for inducing the clinical signs and symptoms of in-
flammation [21].
Previous data have suggested that JE is more preva-
lent than JSN in early RA, as well as in advanced RA,
and that the two processes are partly independent of
each other [22]. It remains to be elucidated whether an
individual joint with existing JSN and no signs of clin-
ical synovitis is predisposed to future development of
JE. Similarly, the relationship between existing JE and
new onset of JSN needs further consideration. In the
present analysis, we evaluated the effects of three dif-
ferent therapies, MTX monotherapy, adalimumab
(ADA) monotherapy, and ADA +MTX, on the relation-
ship between existing JSN, clinical synovitis, and the
predisposition of future JE development and, similarly,
existing JE, clinical synovitis, and the predisposition of
future JSN development in individual joints using data
from a randomized, controlled trial in a population of
patients with early RA.Methods
Study design and patients
Data from patients in the Prospective Multi-centre Ran-
domised, Double-Blind, Active Comparator-Controlled,
Parallel-Groups Study Comparing the Fully Human Mono-
clonal Anti-TNFα Antibody Adalimumab Given Every Sec-
ond Week With Methotrexate Given Weekly and the
Combination of Adalimumab and Methotrexate Adminis-
tered Over 2 Years in Patients With Early Rheumatoid
Arthritis (PREMIER; NCT00195663) were used for all ana-
lyses [14]. PREMIER was a 104-week, phase 3, randomized,
placebo-controlled trial of ADA in an MTX-naïve popula-
tion with early RA. Adult patients (≥18 years of age) diag-
nosed with RA by the 1987 revised American College of
Rheumatology criteria [23], with disease of <3 years dur-
ation, were eligible for enrolment if they satisfied entry cri-
teria, as previously described [14]. All patients provided
written, informed consent, and the study protocols and in-
formed consent forms were approved by the local institu-
tional review boards or independent ethics committees at
participating sites (see Additional file 1). The study was
conducted in accordance with the principles of the Declar-
ation of Helsinki and good clinical practice.Radiographic, clinical, and functional assessments
Data for all evaluable joints with JE and JSN measures at
26 and 52 weeks and clinical synovitis assessments from
weeks 26 to 52 were included in this post hoc analysis.
Week 26 was chosen for the baseline assessment of JE,
JSN, and synovitis because all patients had active disease
at week 0; therefore, it is likely that many of the joints
assessed would have shown clinical synovitis at the earl-
ier time. Using week 26 as the new baseline facilitated
evaluation of the relationship between JSN and JE, inde-
pendent of clinical synovitis, since a greater proportion
of patients would be expected to be free of swelling after
26 weeks of treatment.
Recent onset of JE/JSN was defined as the lack of JE/JSN
at week 26 but JE/JSN presence at week 52. In contrast,
existing JE/JSN was defined as the presence of JE/JSN at
week 26. Clinical synovitis was assessed through swollen
joint counts at specified visits occurring between weeks 26
and 52 (every 2 to 8 weeks). Ever swelling was defined as
the presence of swelling within the individual joint at any
visit from weeks 26 through 52. Radiographs of the hands
(posteroanterior view) and feet (anteroposterior view)
were taken at week 26 and week 52. Two readers, blinded
to patient and sequence, evaluated joints (yes/no) indi-
vidually for bone erosion (JE) and cartilage destruction
(JSN), and only the subset of joints that were evaluated for
JE and JSN and clinical synovitis were considered in the
present analysis. The average score from the two readers
was used for JE/JSN, and the presence of JE/JSN was de-
fined as the average score >0 (operationalized as a dichot-
omous variable: a score of 0 versus a score >0). In the
present analysis, only scores for the metacarpophalangeal
(MCP) joints 1 to 5, proximal interphalangeal (PIP) joints
2 to 5, and metatarsophalangeal (MTP) joints 1 to 5 (total
of 14 joints bilaterally) were assessed. Joints with recent
onset of JE/JSN at week 52 were separated based on the
presence or absence (dichotomous variable) of JSN/JE at
week 26, respectively.
Statistical analysis
Multivariate logistic modeling was used to characterize
the dependence of JE/JSN onset at 52 weeks, which was
selected because of the quantity of data available, on the
following independent variables: ever swelling during the
evaluable time (yes versus no), JE/JSN presence at 26 weeks
(yes versus no), treatment, joint type (MCP, PIP, MTP),
and body position (left, right). Alternatively, continuous
JE/JSN scores, instead of the dichotomous variable, JE/JSN
presence at week 26, were used in a multivariate logistic
model to evaluate consistency in the models. In addition,
analyses were also performed within each treatment arm
(treatment no longer an independent variable) and for
each individual joint (joint type and body position no lon-
ger independent variables).
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Baseline demographics and disease characteristics
This post hoc analysis evaluated joint-level data from
631 of the 799 patients randomized to MTX monother-
apy (n = 202), ADA monotherapy (n = 203), or ADA +
MTX combination therapy (n = 226) in PREMIER who
had radiographs available at weeks 26 and 52 [14]. Both
baseline demographics and disease characteristics were
comparable among the three treatment groups (Table 1).
The mean RA duration at baseline was 0.7 to 0.8 years,
and there were similar percentages of patients who were
rheumatoid factor-positive among each of the treatment
arms. Approximately one third of the patients in each
group had previously taken disease-modifying antirheu-
matic drugs (DMARDs) and used corticosteroids at base-
line. The patients overall had a baseline 28-joint disease
activity score based on C-reactive protein (DAS28-CRP)
of 6.3 ± 0.9, and reported severe disability (disability index
of the health assessment questionnaire) in each of the
treatment arms. Mean baseline modified total Sharp score
(mTSS), JE, and JSN scores were higher in the MTX
monotherapy treatment group than in the ADA mono-
therapy or ADA+MTX treatment groups. Patient disease
characteristics at baseline were comparable with those of
the overall PREMIER population and were indicative of a
population with early and severely active RA.
Of the 17,644 evaluable joints, 275 joints (1.6%), from
189 patients, lacked JE at week 26 but had evidence ofTable 1 Baseline demographic and disease characteristics
Baseline characteristic MTX ADA ADA +MTX
(n = 202) (n = 203) (n = 226)
Age, years 52.7 ± 13.3 52.0 ± 12.9 52.0 ± 14.1
Female, n (%) 149 (73.8) 154 (75.9) 159 (70.4)
Disease duration, years 0.8 ± 0.9 0.7 ± 0.8 0.7 ± 0.8
Rheumatoid factor-positive, n (%) 172 (85.6) 172 (84.7) 191 (84.5)
Prior DMARD use, n (%) 61 (30.2) 68 (33.5) 69 (30.5)
Baseline corticosteroid use, n (%) 68 (33.7) 74 (36.5) 81 (35.8)
SJC (0 to 66) 22.3 ± 12.0 21.6 ± 10.4 21.4 ± 11.5
TJC (0 to 68) 32.0 ± 14.3 32.5 ± 13.8 30.5 ± 14.5
DAS28-CRP (0 to 10) 6.3 ± 0.9 6.3 ± 0.9 6.3 ± 0.9
DAS28-CRP ≥5.1, n (%) 183 (93.4) 177 (88.9) 196 (90.3)
HAQ-DI (0 to 3) 1.5 ± 0.7 1.6 ± 0.6 1.5 ± 0.6
CRP, mg/dL 4.0 ± 4.0 3.8 ± 3.6 3.9 ± 4.1
mTSS (0 to 398) 22.5 ± 22.6 19.0 ± 18.9 18.7 ± 20.7
JE (0 to 230)a 14.0 ± 13.7 11.5 ± 11.5 11.4 ± 12.9
JSN (0 to 168) 8.5 ± 10.9 7.5 ± 8.8 7.3 ± 9.4
All values are mean ± SD, unless otherwise indicated. aP = 0.047 for pairwise
comparison of MTX versus ADA +MTX. MTX, methotrexate; ADA, adalimumab;
DMARD, disease-modifying antirheumatic drug; SJC, swollen joint count; TJC,
tender joint count; DAS28, 28-joint disease activity score; HAQ-DI, disability
index of the health assessment questionnaire; CRP, C-reactive protein; mTSS,
modified total Sharp score; JE, joint erosion; JSN, joint space narrowing.JE by week 52 (Table 2). In addition, 226 (1.3%) joints,
from 153 patients, lacked JSN at week 26 but had evi-
dence of JSN by week 52. A total of 59 out of 275 joints
(21.5%) with recent onset JE had existing JSN at week
26; in contrast, the majority of joints (133/226, 58.8%)
with recent onset of JSN had existing JE at week 26.
Joints with existing JE had a larger number of affected
joints with recent onset JSN at week 52 than existing
JSN with recent onset JE, which suggests that existing JE
may have a greater impact on JSN appearance than
existing JSN has on the appearance of JE in patients with
early RA. There were 626 (99.2%) patients with at least
one unaffected joint, as they did not have JE at week 26
or 52 nor JSN at week 26 or 52. Furthermore, 9,626
joints had no presence of JE or JSN, and, on average, 15
(of the 28 assessed) joints per patient were never af-
fected by JE or JSN (data not shown).
Association between existing JE, clinical synovitis, and
treatment, and JSN onset in joints overall
In the multivariate logistic analyses, ever swelling from
weeks 26 through 52 (odds ratio (95% CI), 1.95 (1.55,
2.45)) and existing JE at week 26 (2.19 (1.76, 2.72)) were
significant predictors of JSN onset at week 52 (Figure 1A).
The result from using continuous JE scores at week 26
validated the primary results, where higher JE scores at
week 26 were associated with an increased risk of JSN
onset by week 52 (1.80 (1.53, 2.10)). Treatment with
ADA, either as monotherapy or in combination with
MTX, reduced the risk of JSN development at week 52
for joints when controlling for other characteristics (for
example, ever swelling, existing JE, et cetera) compared
with MTX (Figure 1B). Ever swelling during the assess-
ment period was a predictor of JSN recent onset in indi-
vidual joints of patients treated with MTX (2.31 (1.55,
3.44)) and ADA (2.25 (1.55, 3.26)) monotherapy, but to
a lesser, though not significant, extent of patients treated
with the combination (1.31 (0.86, 1.99)) (Figure 1C),
similar to the observed association between existing JSN
and recent JE onset. Irrespective of treatment group, theTable 2 Numbers of patients and joints with recent
onset>a joint erosion (JE)/joint space narrowing (JSN) at
52 weeks exhibiting JSN/JE at week 26b
Variable Patients Joints
n (%) (n = 631c) (n = 17,644)
Recent onset JE with existing JSN 46 (7.3) 59 (0.3)
Recent onset JE without existing JSN 143 (22.7) 216 (1.2)
Recent onset JSN with existing JE 88 (13.9) 133 (0.8)
Recent onset JSN without existing JE 65 (10.3) 93 (0.5)
aNo JE/JSN at week 26 but JE/JSN present at week 52. bExisting JE/JSN is
defined as the presence of JE/JSN at week 26. cPatients could have different
JE/JSN patterns for the joints that were evaluated.
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Figure 1 Association between existing JE, clinical synovitis, and treatment, and JSN onset in joints overall. (A) Ever swelling from 26 through
52 weeks and joint erosion (JE) presence at week 26 were independent predictors of presence of joint space narrowing (JSN) at 52 weeks.
(B) The effect of treatment on the development of JSN at 52 weeks in joints with similar characteristics. (C) The association between ever swelling
from 26 through 52 weeks and presence of JE at week 26, and JSN presence at 52 weeks, by treatment group. MTX, methotrexate; ADA, adalimumab.
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JSN presence at week 52.
The association between existing JSN, clinical synovitis,
and treatment, and JE onset in joints overall
In the multivariate logistic analyses, ever swelling from
weeks 26 through 52 and also existing JSN at week 26 were
significant predictors of JE onset at week 52 (Figure 2A)
(1.89 (1.54, 2.33) and 1.85 (1.48, 2.33), respectively). The
result from using continuous JSN scores at week 26 vali-
dated these results, where higher JSN scores, indicative of
more extensive cartilage damage, at week 26 were also
associated with an increased risk of JE onset by week 52
(1.36 (1.14, 1.63)). Treatment with ADA, either as mono-
therapy or in combination with MTX, reduced the risk of
JE development at week 52 for joints when controlling for
other characteristics (for example, ever swelling, existing
JSN, et cetera) compared with MTX (Figure 2B). During
the treatment period, ever swelling was a significant pre-
dictor of JE recent onset in individual joints of patients
treated with both MTX (2.20 (1.61, 3.01)) and ADA (2.05
(1.45, 2.91)) monotherapy (Figure 2C), but not of patients
treated with the ADA+MTX combination (1.17 (0.76,
1.82)). These findings confirm the previous observation
that ADA +MTX controls bone damage independently of
its ability to control for disease activity [24]. Existing JSNat week 26 was also a predictor of JE onset in patients
treated with MTX monotherapy (2.47 (1.75, 3.48)) or
ADA+MTX combination therapy (1.60 (1.01, 2.54));
however, existing JSN did not significantly predict JE onset
in patients who received ADA monotherapy (1.38 (0.94,
2.02)).
The association between existing JE and clinical synovitis,
and JSN onset in individual joints
Individual joint assessments indicated that existing JE,
independent of swelling, was a significant predictor of
JSN onset in higher proportions of MTPs (7/10) than
PIPs (1/8) or MCPs (1/10) (Figure 3A). Clinical synovitis
was significantly associated with the onset of JSN in
higher proportions of MTPs (3/10) than MCPs (2/10) or
PIPs (1/8) (Figure 3B); however, the latter associations
occurred in lower proportions than were observed with
existing JE.
Discussion
Joint damage is a hallmark of RA, and previous data
have suggested that the processes of JE and JSN are
partly independent of each other [22]. The objective of
this study was to evaluate whether the presence of JE in
an individual joint can lead to the development of JSN
and if existing JSN leads to new onset of JE, in the
Increasing Odds of JE Development
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Figure 2 Association between existing JSN, clinical synovitis, and treatment, and JE onset in joints overall. (A) Ever swelling from 26 through
52 weeks and presence of joint space narrowing (JSN) at week 26 were independent predictors of presence of joint erosion (JE) at 52 weeks.
(B) Effect of treatment on the development of JE at 52 weeks in joints with similar characteristics. (C) Association between ever swelling
from 26 through 52 weeks and presence of JSN at week 26, and presence of JE at 52 weeks, by treatment group. MTX, methotrexate; ADA, adalimumab.
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existing JE may have a great impact on JSN develop-
ment, and even more so than existing JSN has on subse-
quent JE development. Treatment with the combination
of ADA +MTX prevents JE and JSN progression inde-
pendently of its ability to suppress clinical synovitis and,
furthermore, limits JE and JSN onset/progression in
joints with existing damage. Additionally, weight-bearing
joints, such as MTP joints, with JE may be at increased
risk for JSN when compared with MCPs and PIPs.
The majority of previous analyses focused on combin-
ing all joints together, and, therefore, the impact of ther-
apy, irrespective of inhibition of disease activity, was
highly biased by the fact that synovitis may have not
been observed in the very same joints than those that
showed radiographic progression. Similar to the TEMPO
trial [25], our study isolated each joint and recorded
whether or not they had synovitis and/or onset of JE orJSN. Thus, at a joint level, we have shown that ADA +
MTX prevents JE and JSN by effects beyond its ability to
control for synovitis.
This analysis expands upon previous findings by sug-
gesting that existing JE may predispose joints to further
develop JSN, irrespective of the presence or absence of
clinical synovitis. In addition, the independent impact of
existing JSN on new onset of JE was also demonstrated
in this study. Additionally, these findings suggest that
joint erosions are more prevalent than JSN and occur
earlier in the disease. However, this may also be a conse-
quence of discrepancy in the scoring techniques related
to JE and JSN, which may have distinct sensitivities to
change. This post hoc analysis demonstrated that over
50% of the evaluable joints that had existing JE at
week 26 developed recent onset of JSN, while only
21.5% of those joints with existing JSN at week 26 deve-
loped onset of JE. In addition, ever swelling and existing
0.1 1 10
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Figure 3 Association between existing JE, clinical synovitis, and JSN, and JSN and JE onset in individual joints. (A) Odds ratios (95% CI) for the
influence of existing joint erosions (JE) to predict future onset of joint space narrowing (JSN) in individual joint assessments. (B) Odds ratios (95% CI) for
the influence of joint swelling to predict future onset of JSN in individual joint assessments. (C) Odds ratios (95% CI) for the influence of existing JSN to
predict future onset of JE in individual joint assessments. (D) Odds ratios (95% CI) for the influence of joint swelling to predict future onset of JE in
individual joint assessments. MCP, metacarpophalangeal; L, left; R, right; PIP, proximal interphalangeal; MTP, metatarsophalangeal.
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week 52, while ever swelling and existing JE at week 26
were significant predictors of JSN onset at week 52.
Higher JSN or JE scores at week 26 were associated with
an increased risk of JE or JSN onset by week 52, respect-
ively, and these results further enhance the idea that the
two processes are intertwined. In line with previous find-
ings, our study also showed that treatment with ADA,
either as monotherapy or in combination with MTX, re-
duced the risk of both JE and JSN development at week
52 for joints with similar characteristics when compared
with MTX monotherapy.
Additionally, it has been shown here that weight-
bearing MTP joints with JE may be at an increased risk
of JSN when compared with MCPs and PIPs. Studies by
Goldring et al. [26] suggest that chondrocytes can be ac-
tivated by both pressure and mechanical stress, and are
capable of stimulating signaling pathways that causecartilage damage and defective repair mechanisms. Thus,
a change in the geometric orientation of the joints, sub-
sequent to significant JE, may result in increased pres-
sure on the cartilage and activation of the chondrocytes,
leading to JSN, which may be more prevalent in weight-
bearing joints as they may be more sensitive to this
mechanism of action.
A final question arises: can we possibly explain why
joint erosions are a risk factor for development or pro-
gression of cartilage damage even in the absence of
synovitis? The answer can only be speculative, but may
give rise to further considerations. First, as discussed
above, there may be mechanical changes due to the
presence of erosions with increased cartilage wear. Sec-
ond, a joint should only be diagnosed as swollen if the
swelling is beyond doubt [27]. Thus, synovitis may exist
in some joints without being clinically overt [28], and
the presence of power Doppler signals of 3, in the
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sociated with decreased physical function [29]. Third, RA
patients have higher articular TNF levels than patients
with less destructive forms of arthritis [30] and osteoclas-
togenesis requires higher amounts of TNF than synovial
inflammation [21]; thus, incomplete TNF inhibition will
reduce bioactive TNF levels below the threshold of osteo-
clastogenesis stimulation, even if leaving sufficient TNF to
continue eliciting inflammation [31]. Therefore, it may be
assumed that, even in subclinical synovitis, sufficiently
high TNF concentrations arise that may elicit cartilage
damage. Fourth, in a TNF-driven experimental model of
RA, it has been seen that severe cartilage damage requires
attachment of the synovial membrane to the cartilage sur-
face [32]; aside from subclinical disease, attachment may
persist for some time even when overall synovitic activity
diminishes. Finally, bone erosions in RA frequently occur
at the cartilage bone junction with synovial tissue (pannus)
undermining cartilage and, thus, attacking cartilage in a
forceps-like manner from above and below. Even if syno-
vitis fades away, such double-edged activity may persist
for some time, allowing cartilage damage to accumulate.
As stated above, whether any one or all of these ideas play
causative roles in our observation remains elusive, but
they may provide hypotheses that lend themselves to fur-
ther investigations in experimental settings.
The finding that progression of JE is absent while pro-
gression of JSN continues indicates that the two pro-
cesses can be uncoupled. This concept is supported by
data from an experimental model [21] that demonstrated
that TNF blockade can interfere with osteoclastogenesis
and expression of osteoclast-related genes, such as ca-
thepsin K, and thus inhibit the erosive process while
simultaneously leaving IL-1 gene expression fully intact.
Because IL-1 is a major driver of cartilage damage, low
IL-1 levels protect against cartilage damage even in an
environment of high TNF levels [32]. In other words,
cartilage damage is dependent on TNF and IL-1 in the
joints, causing synovitis, whereas the development of
erosions is dependent on the formation of osteoclasts,
which requires more TNF than does synovitis. Condi-
tions in our study were TNF inhibiting we can speculate
that the TNF inhibition may have been sufficient to
suppress osteoclastogenesis, but insufficient to prevent
synovitis. Clinically, this would translate to a joint with
swelling and progression of JSN, but without progression
of erosions.
One of the limitations of our study is that JSN is not a
direct measure of cartilage damage. The contribution of
damage from the surrounding tissues is less likely to
occur in patients with early RA; however, although our
results should be validated in other RA populations,
PREMIER was a study of patients with early RA and it is
unlikely that major soft tissue changes occurred withinthe one-year period related to this analysis, especially as
all patients received active medication.
Conclusions
In summary, our results suggest that existing JE or JSN
not only leads to more JE or JSN, but, at the joint level,
existing JE may also lead to JSN onset in joints with no
clinical synovitis. Similarly, existing JSN may also lead to
JE onset in joints with no clinical synovitis. Both the
combination of ADA +MTX and ADA monotherapy
were associated with lower risk of JE or JSN onset than
was MTX monotherapy in individual joints with similar
characteristics, irrespective of the presence of synovitis.
Given the impact of JSN on physical function early in
the disease course, this further highlights the need for
effective therapies that can rapidly control for synovitis
and inhibit the onset of both JE and JSN.
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